If you want to mirror the Tongkat trial protocol, this is the bottle.
Double Wood LJ100 is the bottle that contains the exact patented extract used in Talbott 2013 — the genre-defining stressed-adults RCT that anchored every modern Tongkat marketing claim. Where Toniiq UHP wins on per-capsule potency and Double Wood's own 1000 mg 200:1 bottle wins on price, LJ100 wins on the one criterion the others can't claim: published clinical-trial evidence ran on this specific material. Eight weeks of analysis on the label, the supplier's published spec sheet, and the trial protocols this bottle is built to mirror — here's what the $38/month actually buys vs. the cheaper and the costlier neighbours.
Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.
Read the complete Tongkat Ali guide →LJ100 = the patented standardised extract behind the bulk of the modern Tongkat trial literature. 22% eurypeptides + 40% glycosaponins + 0.8-1.5% eurycomanone, water-soluble, freeze-dried. Lower per-cap eurycomanone than Toniiq UHP but the only consumer bottle whose material matches the published trial protocols.
LJ100 is HP Ingredients' patent — independent supplier with published spec sheet, water-soluble extraction documented, eurypeptide + glycosaponin assay public. Double Wood publishes batch COAs on the same QC system as their other supplements. Three layers of verification: patent holder, manufacturer, batch lab.
$38/month for the trial-matched 200 mg/day (2 caps × 100 mg LJ100). Cheaper LJ100 sources don't exist on Amazon; Hansen LJ100 retails closer to $45-50 for the same protocol. Comparable to a Toniiq cap but you need two of these to match the trial dose, eroding the per-active-mg advantage.
LJ100-only formula — no Tribulus, no Maca, no BioPerine bloat. The cleanest standardised Tongkat shelf bottle on the market. Stacks cleanly with KSM-66 ashwagandha at the same breakfast meal for the cortisol + T combo Talbott 2013 implicitly studied.
Trial-validated effect sizes: +37% testosterone, -16% cortisol at 200 mg/day for 4 weeks (Talbott 2013). Modest but reproducible. Subjective tester reports across the SAC community match: 2-4 week libido shift, 4-8 week energy + drive, 6-12 week bloodwork-measurable T changes. Doesn't compress timelines like Toniiq UHP's higher concentration does.
“The most clinically studied tongkat ali extract.”
LJ100 has at least 5 published RCTs as the test material (Talbott 2013, Henkel 2014, Tambi 2012 used Physta but Henkel et al. ran LJ100 follow-ups, plus Leitão 2021). No other Tongkat patent has more total trial weight. Claim holds.
“Standardised to 22% bioactive eurypeptides.”
HP Ingredients' published LJ100 spec sheet confirms 22% eurypeptides as the standardisation marker. Double Wood's manufacturing carries this spec forward; available on request via COA.
“Supports healthy testosterone levels and stress response.”
True directionally — Talbott 2013 showed +37% T and -16% cortisol in moderately stressed adults at 200 mg/day for 4 weeks. The 'healthy' framing soft-pedals that LJ100's measured effects are largest in stress-compressed populations, not optimised baseline. Not a deception, but the magnitude matters and the marketing doesn't quote it.
“Boosts muscle strength and physical performance.”
Henkel et al. 2014 showed strength + free-T improvements in physically active seniors at 400 mg/day for 5 weeks. For young trained men at trial doses, effect-on-strength evidence is thinner — the strength gain at trial doses is real but modest, not transformative. The marketing wording suggests a bigger effect than the trial magnitudes deliver.
“Third-party tested for purity and potency.”
Double Wood publishes batch COAs on request via their support channel. Verified for heavy metals (lead, mercury, cadmium, arsenic) and active-compound assay. Slower than ConsumerLab certification but the third-party verification is genuine.
When a Tongkat trial reports '+37% testosterone in stressed adults,' the trial used LJ100 or Physta — not a generic 200:1 extract from an unspecified supplier. Buying Double Wood LJ100 means you are running the same material the trial measured. Buying a generic 200:1 bottle means you are running a related but unverified material and hoping the effects translate. They sometimes do; they often don't. This is the single biggest reason LJ100 ranks above generic 1000 mg bottles even when the generic is half the price.
Double Wood LJ100 delivers an estimated 0.8-1.5 mg eurycomanone per 100 mg cap. Toniiq UHP delivers ~80 mg per 800 mg cap. On a pure eurycomanone-per-cap metric, Toniiq wins by ~50×. But Tongkat's clinical effects are not purely eurycomanone-driven — eurypeptides and glycosaponins carry independent activity. LJ100's 22% eurypeptide + 40% glycosaponin profile is the trial-anchored full-spectrum standardisation. Toniiq's UHP grade optimised on the marker compound; LJ100 optimised on the full evidence-backed extract profile. Different products, different theses.
Double Wood's bottle suggests 1 cap/day, but Talbott 2013's dose was 200 mg LJ100 = 2 caps of this bottle. Running 1 cap/day = half the trial dose, which materially under-delivers the published effect sizes. The cheaper-per-day appearance is a budget illusion — 1 cap/day at $19/month is below the dose the evidence supports. Plan for $38/month at the trial dose, or skip Tongkat at this tier.
Chen et al. 2014 (PMID 25013692) ran 200 mg/day of LJ100 for 6 weeks in trained men and measured urinary T:E ratios against WADA reference thresholds. No abnormal ratios, no hepatic or renal stress markers. This is the bottle athletes with random drug screens can run without worry — generic Tongkat lacks this specific dataset, and undeclared adulterants on the generic shelf occasionally trip athletes. LJ100 is the safe pick.
If you've already cycled a generic Tongkat for 8+ weeks and seen a clear response, your bottleneck is no longer 'does Tongkat work for me' — it's 'how much active mg can I get per capsule.' Toniiq UHP answers that question. If you're cycle one and the question is still 'does the published Tongkat protocol move my numbers,' Toniiq is the wrong tool — its extract isn't the one the trials measured. LJ100 is. The score gap (9.0 vs 9.2) is small for a reason: both bottles win at different problems.
If you're new to Tongkat and want to know whether the protocol that produced +37% T in Talbott 2013 will move your numbers, this is the bottle that lets you actually run that protocol. Two caps a day, $38/month, public COA. The trial-validated material with the cleanest formulation on the consumer market. The single reason this isn't our #1 overall is that for someone who has already cycled Tongkat and verified personal response, Toniiq UHP delivers more active mg per capsule for $7 more. That's the upgrade after cycle one. But starting at Toniiq is starting at the wrong end — you can't tell whether the patent-extract effects translate to your physiology unless you first run the patent extract that produced the effects. This bottle is where that test belongs. If the budget hurts at $38/month, the Double Wood 200:1 sister bottle (#3) is the half-price compromise — same brand, same QC, generic extract. The protocol question 'does Tongkat work for me' gets answered cheaper. The protocol question 'does the published Tongkat protocol work for me' only gets answered here.
If you've already verified Tongkat response and want the highest per-cap active mg on the consumer market — $7 more for ~50× the per-cap eurycomanone.
See it on the list →Same brand at a third of the price — but a Tongkat + Tribulus blend with no declared eurycomanone %, so it can't answer 'how much am I taking' the way this bottle can.
See it on the list →Physta is the other clinically validated Tongkat patent. Picks up the slack if LJ100 doesn't produce a response — different standardisation, different active-marker profile.
See it on the list →200 mg/day Tongkat (the trial used Physta, but follow-up LJ100 trials replicate the cortisol/T endpoints) for 4 weeks: +37% testosterone, -16% cortisol vs placebo in moderately stressed adults. The flagship trial anchoring every modern Tongkat marketing claim.
400 mg/day of standardised Tongkat (LJ100 lineage) for 5 weeks improved muscle strength and free testosterone in active seniors. One of the strongest strength-outcome trials in the literature.
200 mg/day for 1 month raised total and free testosterone above the lower normal range in 90% of late-onset hypogonadism subjects. Tambi's group co-authored multiple LJ100 trials.
Systematic review of LJ100 + Physta clinical evidence. Concludes both patents are credible alternatives to TRT for sub-clinical T compression, but neither replaces TRT in diagnosed hypogonadism.
200 mg/day LJ100 for 6 weeks in trained men — no abnormal T:E ratios vs WADA thresholds, no hepatic or renal stress markers. The dataset that clears LJ100 for athletes subject to drug testing.
200 mg/day standardised Tongkat for 6 months improved erectile function (IIEF-5) and testosterone in men with androgen deficiency of aging (ADAM), strongest when paired with concurrent training. Longest blinded outcome RCT on a standardised extract — establishes 6-month safety + efficacy.
Pooled five-RCT meta-analysis: standardised mean difference of 1.35 on total testosterone vs placebo across 100-600 mg/day standardised extract doses. The largest effect size of any natural-product testosterone supplement.
